HACKENSACK, N.J., Sept. 17, 2019 /PRNewswire/ --Parent Project Muscular Dystrophy (PPMD), a nonprofit organization leading the fight to end Duchenne muscular dystrophy (Duchenne), announced plans to award H. Lee Sweeney, PhD, and his team at the University of Florida (Gainesville) $1 million to continue their exploration of developing novel therapies that can address the causes of dilated heart failure in Duchenne and Becker muscular dystrophy. This $1 million investment is part of PPMD's Cardiac Initiative and a direct result of the Duchenne community's generosity during the organization's 2018 end of the year campaign, as well as the support of other Duchenne families and foundations, including the Killian Family, Team Joseph, Kindness Over Muscular Dystrophy, Another Day for Gray Foundation, and Small Heroes Foundation.
Duchenne isthe most common fatal genetic disorder diagnosed in childhood, affecting approximately one in 5,000 live male births. Duchenne is caused by a change in the dystrophin gene. For people with Duchenne, cardiac disease is an area of great concern. The absence of dystrophin in the heart contributes to a progressive deterioration of cardiac muscle and eventual dilated cardiomyopathy (DCM) or heart disease.
Gene therapy, utilizing AAV vector as the delivery vehicle, provides a potential strategy to deliver transgenes targeting the mechanisms underlying the development of dilated cardiomyopathy. This funding supports the development of a heart specific therapy using an AAV vector containing two transgenes to restore calcium handling and prevent mitochondrial dysfunction. This therapy will potentially be able to treat the hearts of people living with Duchenne and Becker, in a way that is independent of, or complementary to, micro-dystrophin based gene therapy.
PPMD's Founding President and CEO, Pat Furlong, lost both of her sons to heart failure resulting from Duchenne, so this project is particularly meaningful to her and her family: "Heart issues don't just affect some people with Duchenne; they affect ALL people with Duchenne. And while we have improved cardiac care in Duchenne, we still need treatments that repair our children's hearts. Since our organization began 25 years ago, we have been asking questions and trying to better understand the effect of this disease on the heart. Chris and Patrick died of heart failure, so the heart is at the center of Duchenne for me. That's why I am extremely proud to announce this $1 million investment into a gene therapy with the potential to heal the hearts of our loved ones. I am grateful to Dr. Sweeney and the amazing team at University of Florida, as well as the families in our community who believe in our mission and gave generously to help fund the fight to end Duchenne."
Dr. Sweeney, who has a long history in Duchenne research and has worked with PPMD for over two decades, says that PPMD's funding comes at a critical moment in the development of gene therapy: "These are exciting times for gene therapies especially for gene therapies for Duchenne and Becker muscular dystrophy. However, while the current therapies may potentially help the skeletal muscles of patients, there is more to learn and to develop before we can be confident that we are doing all we can for the hearts of patients. The funds provided by PPMD will allow us to move faster toward the goal of creating the best possible gene therapy for the hearts of people with Duchenne and Becker."
Dilated cardiomyopathy (DCM) is the most common type of human cardiomyopathy, occurring mostly in adults 20 to 60. It affects the heart's ventricles and atria, the lower and upper chambers of the heart, respectively. Most forms of DCM are acquired forms from a number of causes that include coronary heart disease, heart attack, high blood pressure, diabetes, thyroid disease, viral hepatitis, and viral infections that inflame the heart muscle. In the case of certain forms of Becker, as well as in most cases of Duchenne, cardiomyopathy can ultimately limit the patient's survival.
While cardiomyopathy associated with Duchenne is technically a dilated cardiomyopathy that progresses to heart failure, many clinicians don't consider it a typical DCM because the patients' hearts don't tend to dilate until rather late in the disease progression. However, this is likely due to the fact that the hearts are not significantly burdened because of the patients' skeletal muscle disease and lack of ability to exercise.
Although Duchenne hearts do not dilate until late in disease progression, they get progressively stiff at earlier time points. This is clearly due to progressive fibrosis, and is slowed by the use of anti-fibrotic drugs, such as ACE inhibitors or ARBs (Angiotensin II Receptor Blockers). Interestingly, because of the fibrosis and lack of burden on the heart, the left ventricular chamber is actually smaller in diameter than normal after age 8 and until late in disease progression, when it begins to dilate. Again, consistent with this being related to the fibrosis is the fact the individuals who were not given ACE inhibitors early in disease progression show the smallest ventricular diameters and progress the fastest once they begin to dilate.
In the case of Becker, there clearly is a subset of Becker patients that show a disproportionately rapid progression of their cardiac disease as compared to their skeletal muscle disease. This has called attention to the fact that there are some regions of the dystrophin molecule that are more important in the heart than they are in skeletal muscle, likely because of components that differ in importance or even in identity between the heart and skeletal muscle.further explore a novel gene therapy approach that will target the heart in people living with Duchenne and Becker muscular dystrophy.
To learn more about PPMD's Cardiac Initiative, click here.
About Parent Project Muscular Dystrophy
Duchenneis a fatal genetic disorder that slowly robs people of their muscle strength. Parent Project Muscular Dystrophy (PPMD) is the largest most comprehensive nonprofit organization in the United States focused on finding a cure for Duchenneour mission is to end Duchenne.
We demand optimal care standards and strive to ensure every family has access to expert healthcare providers, cutting edge treatments, and a community of support. We invest deeply in treatments for this generation of Duchenne patients and in research that will benefit future generations. Our advocacy efforts have secured hundreds of millions of dollars in funding and won two FDA approvals.
Everything we doand everything we have done since our founding in 1994helps those with Duchenne live longer, stronger lives. We will not rest until we end Duchenne for every single person affected by the disease. Join our fight against Duchenne at EndDuchenne.org and follow PPMD on Facebook, Twitter, andYouTube.
SOURCE Parent Project Muscular Dystrophy
Follow this link:
- The Wet AMD Gene Therapy Race - Adverum Biotechnologies Vs. Regenxbio - Seeking Alpha - June 5th, 2020
- Cell and gene therapies - Lexology - May 28th, 2020
- Bicoastal startup Kriya Therapeutics to grow gene therapy manufacturing in NC - WRAL Tech Wire - May 28th, 2020
- Expression Therapeutics Announces IND Approval by the FDA for Hemophilia A Gene Therapy | DNA RNA and Cells | News Channels - PipelineReview.com - May 28th, 2020
- Troubleshooting the Development of New Gene Therapies - Technology Networks - May 28th, 2020
- Lab Mice Shed Fat and Build Muscle with Gene Therapy - The Great Courses Daily News - May 28th, 2020
- Reversing SHANK3 mutations in mice mitigates autism-like traits - Spectrum - May 28th, 2020
- Orchard Therapeutics to Present at Virtual Investor Conferences in June - Yahoo Finance UK - May 28th, 2020
- Gene Therapy market worldwide is projected to grow by US$3.3 Billion - GlobeNewswire - May 28th, 2020
- Generation Bio tees up $125M IPO to push next-gen gene therapies - FierceBiotech - May 27th, 2020
- Expression Therapeutics Announces IND Approval by the FDA for Hemophilia A Gene Therapy - PRNewswire - May 27th, 2020
- Novartis' gene therapy approved in Europe, talks ongoing on price - BioPharma-Reporter.com - May 27th, 2020
- NOVASEP and LYSOGENE Announce their New Collaboration for Development and Production of GM1 Gangliosidosis Gene Therapy Product - Business Wire - May 27th, 2020
- Evox Therapeutics Appoints Martin Andrews as Non-Executive Director - BioSpace - May 27th, 2020
- New Zolgensma 'inflection point' is here as Novartis snags EU nod for SMA gene therapy - FiercePharma - May 27th, 2020
- Gene therapy could help millions of ash trees fight deadly beetle Emerald Ash Borer - inews - May 27th, 2020
- Generation Bio Leads a Trio of Biotech Companies Aiming for the Nasdaq - Xconomy - May 27th, 2020
- European regulators accept FibroGen's anemia drug for review; Passage Bio's lead gene therapy gets more love from the FDA - Endpoints News - May 27th, 2020
- QPS Continues to Expand UPLC-HRMS Quantitation Capabilities to Support Gene Therapy and Protein Drug Development - PRNewswire - May 19th, 2020
- Novartis wins conditional EU approval for gene therapy Zolgensma - Reuters - May 19th, 2020
- The Roller Coaster of Gene Therapy... - Labiotech.eu - May 19th, 2020
- Gene therapy reduces fat and builds muscle in mice - BioNews - May 19th, 2020
- Forget ExerciseThese Mice Got Ripped With Gene Therapy - Singularity Hub - May 19th, 2020
- UPDATED: Pfizer gene therapy ups levels of dystrophin expression in Duchenne trial but another safety setback mars results - Endpoints News - May 19th, 2020
- Thermo Fisher to invest $180M in new gene therapy plant - BioPharma Dive - May 19th, 2020
- Beam Therapeutics Taking Novel Approach to Gene Therapy - Yahoo Finance - May 19th, 2020
- Gene-Therapy Treatments for Tay-Sachs, Sickle Cell to Be Featured in Online Gathering - Barron's - May 19th, 2020
- Sarepta And Dyno Therapeutics Will Develop Next-Gen Gene Therapy Vectors - Contract Pharma - May 19th, 2020
- New gene therapy cuts fat and builds muscle with ease. But theres a catch - Digital Trends - May 19th, 2020
- New Gene Therapy Promises You Will Get Ripped Without Stepping in a Gym - Interesting Engineering - May 19th, 2020
- Merck KGaA adds to gene therapy manufacturing boom with 100M facility in California - Endpoints News - May 19th, 2020
- Japan's health insurance to cover 167 million gene therapy drug - The Japan Times - May 19th, 2020
- COVID 19 PANDEMIC: Gene Therapy Market Is Set To Experience Revolutionary Growth By 2025 - Cole of Duty - May 19th, 2020
- Magenta Therapeutics Presents Data at Annual Meeting of American Society of Gene and Cell Therapy Demonstrating Cells Mobilized with MGTA-145 in a... - May 19th, 2020
- Passage Bio Announces Expansion of Gene Therapy Collaboration with University of Pennsylvania - GlobeNewswire - May 11th, 2020
- Orgenesis sees 1Q revenue rocket driven by its Cell and Gene Therapy Biotech platform - Proactive Investors USA & Canada - May 11th, 2020
- Gene therapy for follistatin mitigates systemic metabolic inflammation and post-traumatic arthritis in high-fat dietinduced obesity - Science Advances - May 11th, 2020
- BioMarin broadens its gene therapy horizons with a new R&D alliance in rare cardio cases - Endpoints News - May 11th, 2020
- BioLife Solutions to Report First Quarter 2020 Financial Results and Provide Business Update on May 14th, 2020 - Chinook Observer - May 11th, 2020
- Adverum soars on early gene therapy data; BerGenBio raises 45.4M on the heels of Covid-19 move - Endpoints News - May 11th, 2020
- Neurophth Therapeutics Announces Presentations at ASGCT and ARVO Annual Meetings - PRNewswire - May 11th, 2020
- Genprex Enters Into Exclusive Worldwide Patent and Technology License Agreement for Combination of its TUSC2 Gene Therapy with Immunotherapies -... - May 11th, 2020
- Study suggests effective fat-reducing therapy - Tech Explorist - May 11th, 2020
- Senti Biosciences to Present on Gene Circuit-Based Therapies at the 2020 ASGCT Annual Meeting - Business Wire - May 11th, 2020
- Hitachi Chemical Advanced Therapeutics Solutions and apceth Biopharma GmbH Enter into Strategic Clinical and Commercial Manufacturing Agreements with... - May 11th, 2020
- Flexion Therapeutics Announces Virtual Poster Presentations for FX201, an Intra-Articular Gene Therapy Candidate for the Treatment of Osteoarthritis,... - May 11th, 2020
- UPDATE Amicus Therapeutics Announces Upcoming Presentations at the American Society of Gene & Cell Therapy 23rd Annual Meeting - GlobeNewswire - May 11th, 2020
- This Gene Is a Molecular "Knob" That Fine-tunes Our Cortex's Electrical Activity - Technology Networks - May 11th, 2020
- Gene Therapy for Rare Disease Market 2020 Coronavirus (Covid-19) Business Impact 2026 Growth Trends by Manufacturers, Regions, Type and Application,... - May 11th, 2020
- Can gene therapy help develop coronavirus vaccine? Researchers banking on this technology for breakthrough - MEAWW - May 11th, 2020
- A Tribute to Max Randell, Gene Therapy Pioneer - PLoS Blogs - April 27th, 2020
- Merck KGaA to spend $110M on new gene therapy facility in California - BioPharma Dive - April 27th, 2020
- Vertex Pharmaceuticals and Affinia Therapeutics Establish Multi-Year Collaboration to Discover and Develop Novel AAV Capsids for Genetic Therapies |... - April 27th, 2020
- Glaucoma can be successfully treated with gene therapy - Telangana Today - April 27th, 2020
- Regenxbio Is A Leader In Gene Therapies - A Case Where The Platform Is Worth More Than The Pipeline - Seeking Alpha - April 27th, 2020
- UK Startup to Manufacture Cell and Gene Therapies with... - Labiotech.eu - April 27th, 2020
- Sangamo- Early-Stage Progress in Gene Therapy - Yahoo Finance - April 27th, 2020
- Inclusive Comprehension 2020: Gene Therapy Market (Trending PDF) Addressing Structure, Scope, Potential, and Growth Prospects Till 2029 - Jewish Life... - April 27th, 2020
- Ziopharm Oncology to Report First Quarter 2020 Financial Results and Host a Conference Call and Webcast on May 7, 2020 - Yahoo Finance - April 27th, 2020
- Lysogene S.A. (EPA:LYS): When Will It Breakeven? - Simply Wall St - April 27th, 2020
- Diabetes reversed in mice with genetically edited stem cells derived from patients - Washington University School of Medicine in St. Louis - April 27th, 2020
- Addressing the potential impact of coronavirus disease (COVID-19) on Hemophilia Gene Therapy Market: Quantitative Analysis from 2019 to 2025 to Enable... - April 27th, 2020
- COVID-19 impact: Gene Therapy Market 2019 Business Insights,Top Companies,Growth, Market Size Global Market Share, Trends, Outlook, Opportunity and... - April 27th, 2020
- Gene Therapy For Inherited Genetic Disorders Market Overview, Top Companies, Region, Application and Global Forecast by 2026 - Latest Herald - April 27th, 2020
- Glaucoma Could Be Successfully Treated With Gene Therapy - Technology Networks - April 26th, 2020
- Reversing diabetes with CRISPR and patient-derived stem cells - FierceBiotech - April 26th, 2020
- Glaucoma can be successfully treated with gene therapy - International Business Times, Singapore Edition - April 26th, 2020
- AskBio acquires BrainVectis to expand its gene therapy portfolio - News.MarketSizeForecasters.com - April 26th, 2020
- 'We're really at a tipping point': COVID-19 brings research into other medical conditions to a grinding halt - CBC.ca - April 26th, 2020
- ThermoGenesis and ImmuneCyte Joint Venture Developing Several Convalescent Plasma and Antibody Therapeutic Approaches Against COVID-19, Featured on... - April 26th, 2020
- Gene Therapy Market : Global Outlook and Forecast 2020-2025 - Surfacing Magazine - April 26th, 2020
- Gene Therapy for Frontotemporal Dementia With a GRN Mutation Gets Fast Track Status - Monthly Prescribing Reference - March 26th, 2020
- Redpin bags A round to advance Chantix-controlled gene therapies - FierceBiotech - March 26th, 2020
- Vycellix and Avectas Announce Collaboration to Advance Next-Generation Solutions for the Optimized Manufacture of Cell & Gene Therapies - BioSpace - March 26th, 2020
- Avectas and Vycellix Announce Collaboration to Advance Next-Generation Solutions for the Optimized Manufacture of Cell & Gene Therapies - BioSpace - March 26th, 2020
- Global Viral Vector and Plasmid DNA Manufacturing Market to Surpass US$ 2,205.6 Million by 2027 - CMI - Yahoo Finance - March 26th, 2020
- Codexis and Takeda partner on gene therapies for rare diseases - Pharmaceutical Technology - March 26th, 2020
- Genprex Strengthens Leadership Team with the Appointment of Two Accomplished Life Science Executives - Yahoo Finance - March 26th, 2020
- Study reveals gene therapy may help in treating cardiac disease - The Siasat Daily - March 26th, 2020
- TCR therapy an attractive alternative to CAR T for immunotherapy - Drug Target Review - March 26th, 2020